EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Current limitations and future opportunities of tracer studies of muscle ageing

Colleen L O'Reilly, Sue C Bodine iD, Benjamin F Miller iD

The Journal of Physiology · 2025-01 · 603 (1) · 7-15

DOI: 10.1113/jp285616 ↗

At a glance

Journal article in The Journal of Physiology, published online on 2023-12-05. Written by Colleen L O'Reilly and 2 co-authors. Institution: Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. Cited 25 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: BLRD VA, NIA NIH HHS, Veterans Association.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The overarching question that we address here is whether current tracer approaches focused on the measurement of protein synthesis are leading us in a fruitful direction to combat muscle loss with age. Because ageing is largely a loss of protein mass over time, logically, the field has focused on improving anabolism. To assess an improvement in anabolism, tracer-based measurement of protein synthesis is often a primary outcome. It is possible that the relative ease of measuring protein synthesis in comparison to breakdown has biased research efforts towards the protein synthesis side of the equation. An additional reason is that some argue that the slowing of protein synthesis and/or anabolic resistance is the primary determinant of muscle loss with age (Burd et al., 2013; Nunes et al., 2022). The statement that 'ageing decreases muscle protein synthesis' often appears without citation because it is a generally accepted 'fact' in the skeletal muscle literature. As far as we can tell, the studies that first led to this conclusion were those studies from the Nair lab that looked at skeletal muscle in ageing humans (Balagopal et al., 1997; Rooyackers et al., 1996). A point of consideration is that these studies were performed with labelled amino acid infusions, the importance of which will be discussed here. The conclusion that ageing decreases muscle protein synthesis has led to interventions for aged muscle, such as amino acid feeding, that focus on increasing protein synthesis through activation of the mechanistic target of rapamycin (mTOR). However, a rigorous evaluation of the literature indicates that there are several contradictory findings to this 'known'. There are studies showing that protein synthesis does not decrease in skeletal muscle with age and, conversely, showing increases in protein synthesis compared to adult muscle (Fuqua et al., 2023; Kimball et al., 2004; Miller et al., 2019). Furthermore, studies in rodent models (Fuqua et al., 2023; Joseph et al., 2019; Tang et al., 2019; White et al., 2016) and humans (Guillet et al., 2004; Markofski et al., 2015) show that mTOR activity is increased in aged muscle and that treatments that inhibit mTOR or slow protein synthesis over the long-term, such as rapalogs (Joseph et al., 2019) and protein or branch chain amino acid restriction (Richardson et al., 2021), improve muscle function with age. Instead of basing interventions and future studies on the premise that protein synthesis uniformly decreases with age, an approach that focuses on proteostatic mechanisms that slow muscle ageing could open new possibilities for interventions. The current overall (but admittedly generalized) framework paints protein synthesis as good and protein breakdown as bad. In other words, it focuses the attention on increasing muscle protein synthesis in aged muscle at the same time as reducing muscle protein breakdown. However, these conclusions are based on a body of literature using approaches that may miss crucial aspects regarding protein turnover, and are also based on the foundation that accumulation of protein mass is the most important target for maintaining muscle function with age. Here, we aim to highlight some methodological considerations to shift the focus of what is important for muscle protein turnover with age. At a minimum, we hope to provide tools that help readers evaluate the literature with a critical eye. Ideally, we hope that the field will adapt some non-traditional isotope approaches to better direct therapeutic efforts. The loss of skeletal muscle function often precedes and exceeds loss of mass, indicating that protein quality is as important as protein quantity. Although muscle mass, and hence protein mass, has an impact on overall function, it is equally important to have the correct proteins for cellular tasks and for those proteins to be assembled properly and function well. The matching of well-functioning proteins to the demands of the cell is referred to as protein homeostasis, or proteostasis. Proteostasis is a self-regulating process through which systems maintain protein functionality at the same time as adjusting to changing conditions. As such, maintaining proteostasis in one cell type may not be the same as in another cell type, or even at different times within a cell type. The dynamic mechanisms through which proteostasis is maintained is a network of complex interrelated cellular activities such as protein biogenesis, folding, transport and degradation that collectively determine proteome structure and function (Balch et al., 2008). This dynamic feature of proteostasis is important when assessing mechanisms because the proteome continually adjusts to the current environment. When these mechanisms fail, there is a loss of proteostasis. The mechanisms that maintain proteostasis become dysregulated with advancing age (Hipp et al., 2019; Taylor & Dillin, 2011). The accumulation of dysfunctional proteins compromises cellular function and responsiveness to cellular stresses leading to age-related deterioration, and more than 50 diseases (Walker & LeVine, 2012). Conversely, the ability to maintain proteostasis slows the ageing process (Balch et al., 2008; Jayaraj et al., 2020; Pride et al., 2015). It is well established in a variety of tissues, including skeletal muscle, that mechanisms of proteostatic quality control fail with advancing age such that decreased proteostasis is a hallmark of ageing (López-Otín et al., 2013). One well described feature of proteostatic decline is the accumulation of protein aggregates that are resistant to turnover. An additional consequence of a decline in proteostasis is increased energetic costs of maintaining the proteome. A decline of protein function in organelles such as the mitochondria compounded by increased energetic costs of maintaining the proteome can result in an increasing strain on the cell to maintain proteostasis. It is important first to distinguish proteostasis from simple changes in protein content. Here, we focus on the proteostatic mechanisms of protein synthesis and protein breakdown. A helpful construct for understanding proteostasis is to consider pools of protein. The proteins entering (synthesis) and proteins leaving (breakdown) constitute the protein 'pool' with synthesis and breakdown together determining the composition of the pool and the rate at which the pool turns over. Furthermore, the balance of synthesis and breakdown determines the size of the protein pool (increases, decreases or stays the same). Protein pools (e.g. skeletal muscle protein pool, extracellular matrix pool, mitochondrial pool or myosin) have progressively become more specific over time because our measurement techniques have become more sensitive. With improved sensitivity there is also improved understanding of the mechanisms of proteostasis. Dufner et al. (2005), Gasier et al. (2009) and Busch et al. (2006) started using deuterium oxide (D2O) for long-term measurements of protein synthesis in the mid 2000s. Our group published our first paper using D2O in 2011 (Robinson et al., 2011), with others thereafter (Wilkinson et al., 2014). The groups that pioneered this work all brought slightly different approaches to its use. Although D2O shares the same precursor-product method of measuring protein synthesis as labelled amino acids, the long-term nature of the labelling introduced new considerations as well as new opportunities (Miller et al., 2020). Early on, we learned that there is not a one-size fits all approach for using D2O. However, each failure taught us something new that informs the current perspective. Here, we use our studies to address what we consider to be crucial considerations and opportunities for the use of D2O for understanding proteostatic mechanisms. We provide these insights in four brief sections: (1) 'muscle' protein synthesis is an oversimplification; (2) the period of measurement is important; (3) the non-steady state must be accounted for and protein breakdown matters; and (4) the number of proteins that are turning over is often overlooked. Although we have focused on muscle ageing, the principles laid out here are relevant to all long-term tracer studies and period of protein loss or gain. Published papers often refer to 'muscle' protein synthesis where muscle is a homogeneous entity with a given protein synthesis rate. However, similar to all tissues, muscle is composed of multiple cell types and, within each cell type, there are thousands of proteins that are independently regulated (Fig. 1). With single cell (which do not include myofibers) and single nuclei (which do include myofibers) sequencing, it is possible to estimate the abundance of cell types. Adult skeletal muscle is composed primarily of mature myofibers and satellite cells, with 55–88% of measured nuclei in mice being myonuclei and 1–4% being satellite cells (Borowik et al., 2023; Dos Santos et al., 2020; Orchard et al., 2021; Perez et al., 2022). Single nuclei studies of mice show that skeletal muscle has 2–4% immune cells, 2–4% smooth muscle cells, 2–7% endothelial cells and 10–19% fibro-adipogenic progenitors (Dos Santos et al., 2020; Orchard et al., 2021; Perez et al., 2022). In humans, the percentage of myonuclei may be slightly higher. What is often overlooked is that the abundance and turnover of proliferative cell types contributes to bulk protein synthesis rates because cell replication requires the doubling of protein content (Miller et al., 2014). Therefore, even though supportive cell types are less abundant than myofibers, they have an important influence on bulk protein synthesis rates. Similar to the differences in the abundance of cell types, there is a large distribution of protein abundances from highly abundant myofibrillar components to less abundant cell surface proteins. The measurement of muscle protein synthesis distills this complexity into a single value, which is largely determined by rapidly turning over proteins and highly abundant proteins (Miller et al., 2015). Protein synthesis is one of the most energy costly processes in the cell. Because there is a finite amount of energy on demand in a cell, increases in the synthesis of some proteins inevitably results in the slowing of the synthesis of others. Translation of proteins is highly regulated as in transcription. It is inconceivable that a single value of 'mRNA transcription' would be published to apply to all individually regulated mRNA in a tissue, yet it is common practice to publish a single value of 'protein synthesis' to represent the making of independently regulated proteins. Admittedly, measuring the synthesis rates of individual proteins is challenging, although the advent of tracer-based proteomic approaches is helping to rectify this need. Using tracer-based proteomics has shown that, even when a specific treatment does not change bulk protein synthesis, the majority of individual proteins within the bulk measurement are changing synthesis rates (Wolff et al., 2021). Ironically, what makes tracer-based proteomics challenging stems from the topic of this section, namely the large differences in abundances and turnover of individual proteins. Newer technology and algorithms for liquid chromatography-tandem mass spectrometry analysis show great promise for capturing a larger number of muscle proteins so that the reporting of 'muscle' protein synthesis could become a thing of the past. One of the primary advantages of using D2O is that it can be used over prolonged periods. This long-term use is facilitated by the ease of administration in drinking water that does not require tethering a human to an i.v. pole or using surgery for an indwelling catheter in rodents. An advantage of the long-term assessment is that it integrates responses over time to understand cumulative responses. With the increased use of D2O for muscle protein turnover measurements, it became clear that rates obtained with D2O were often lower than those from infused amino acids (Gasier et al., 2009). We hypothesized that the length of labelling, not the choice of tracer, was impacting these results. We demonstrated, via a mathematical model, that a short labelling period (e.g. 20 min) could result in 29% higher rates of synthesis than labelling the same protein pool for a period of 6 weeks (Miller et al., 2015). The reason for the difference is the integrated nature of the protein synthesis measurements. As mentioned in the previous section, synthesis values are the integrated average of thousands of individual proteins that have different abundances and synthesis rates. At shorter periods, faster proteins are over-represented in an average synthesis value. As time goes on, the faster proteins reach 100% new (fully turned over), whereas slower proteins increase their contribution to the average value. Therefore, with longer labelling periods, the integrated rates of synthesis are lower because they have increasing representation of slower proteins (Fig. 2). There are several practical issues associated with the choice of labelling period. The first is that the proteins of primary interest by the investigator should inform the period of labelling. In muscle, many investigators are interested in muscle mass, which is primarily determined by the amount of myofibrillar proteins. Others might be interested in mitochondrial proteins aiming to study mitochondrial adaptations. In both cases, these pools of proteins are relatively slow to turn over and are therefore best captured with longer labelling periods. It is worth mentioning that, out of convenience, many studies in the skeletal muscle field use short labelling periods. An extreme example is the 20 min labelling period used in the puromycin labelling method. Our observation of studies that have used the puromycin method is that, when an image of the bands is included, there is sometimes a lack of bands at the higher molecular weight (200+ kDa) where one would expect the myosin heavy chains. This lack of higher molecular weight bands is a concern when one is interested in the contributions of protein synthesis to changes in mass because the method is not measuring the rate of synthesis of the proteins that primarily contribute to mass. In our paper that modelled the impact of labelling period (Miller et al., 2015), we initially recommended 4 weeks of labelling in skeletal muscle. However, as our experience has grown, we have learned that this period can be too long and that there is no one-size-fits-all labelling period. Therefore, each infusion period should be tailored to the specific question and outcome of interest. A second practical consideration is the use of repeated biopsies with long-term labelling studies in human. In studies with amino acid infusions, it was common practice to take repeated biopsies over a 4–12 h period to look at early and late responses. When using D2O, these periods can be days to weeks. However, when using D2O and comparing an outcome from an early biopsy with that of a later biopsy (e.g. early in training and later in training), this approach is flawed. As discussed above, early sampling biases to rapidly turning over proteins, whereas later sampling biases towards proteins with a slower turnover rate. Therefore, the protein pools represented in the synthesis rates of repeated biopsies include different proteins and cannot be compared. We recommend avoiding studies with test/re-test designs when using D2O labelling and limiting the approach to cross-sectional studies. An assumption for isotope studies is that the size of the protein pool of interest is constant over the experimental period. However, the goal of many studies is to understand changes in protein synthesis and breakdown that contribute to a change in muscle protein mass. Traditional approaches using labelled amino acids were typically conducted over a period of hours, where changes in protein mass were minimal. When performing measurements over days to weeks, there are many conditions, such as disuse-induced atrophy and exercise-induced hypertrophy, where the protein product pool is not constant over time. Our observation is that most published studies using D2O do not account for this lack of steady state. A relatively simple way to point out the error is that in a steady state, by definition, protein synthesis equals protein breakdown. When these two are equal, it would not be possible to have a change in protein mass. Therefore, during a period of muscle loss or gain, assuming a constant pool size and steady state is inappropriate. We recently demonstrated that not accounting for a changing product pool size can substantially alter synthesis rate calculations and interpretation of the contributions of synthesis or breakdown to a change in protein mass. To account for changes in protein product pool size during non-steady state conditions, we have developed a model (Miller et al., 2015, 2018), which is similar to others (Bederman et al., 2015; Samarel, 1991), that can express mass changes (e.g. mg day–1) as well as fractional synthesis rate. Expressing rates as percent of absolute mass can be meaningful during changes in pool size. For example, when a protein pool increases from 100 proteins to 200 proteins, an fractional synthesis rate of 10% per day differs in an absolute sense (i.e. mg proteins day–1) as the size of the pool changes. Both rates can provide valuable, but different, insight of the regulation of muscle mass (Fig. 3). An additional benefit of non-steady state equations is that rates of protein breakdown can be calculated to understand individual contributions of changes in synthesis and degradation during gain or loss of mass. There are established protocols using labelled amino acids to measure muscle protein breakdown (Biolo et al., 1994; Zhang et al., 2002). These approaches are somewhat limited for widespread use because of the need for arterial catheterization or multiple muscle biopsies. Furthermore, these approaches captured relatively short periods of time (hours) and relied on a steady state. There was a notable effort to measure protein breakdown using D2O (Holm et al., 2013). This approach required a long pre-labelling period (over 40 days) and a loss of enrichment over time. As a practical point, the approach necessitates a steady state, but, if in a steady state, the breakdown value should synthesis, so not measure We provide two of the consideration of a change in pool size and the ability to synthesis and breakdown are The first has to do with our studies of atrophy using the model et al., 2020). One primary outcome in this study was that the period of content. Adult that were for days lower measured by in muscle compared to et al., 2020). was lower during compared to but the rate of degradation was during These results highlight a and for during periods of As a second example, we highlight protein turnover during of mice et al., 2021). At the of a day period of was higher in the compared to The protein synthesis rate over this period was breakdown to Therefore, decreases in protein breakdown was for the accumulation of over this period. these findings point to than synthesis, as a target to muscle In the study by et al. myofibrillar protein turnover was measured during the importance of the non-steady state. Using the fractional synthesis rate calculations by others in the it was calculated that muscle lower protein synthesis rates than or Because a steady state that synthesis equals the calculated breakdown rates were lower than and the by the same However, as mentioned above, this approach is because an rate of myofibrillar protein synthesis and breakdown could not result in a loss of protein mass. using non-steady state it was calculated that protein synthesis is higher in as a percent but less than when as absolute mass Furthermore, rates of breakdown were in muscle th

Subjects

Author keywords

ageingdeuterium oxidesarcopeniaskeletal musclestable isotopes

Authors and institutions

  • Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
  • Oklahoma City Veterans Association, Oklahoma City, OK, USA.

ORCID profiles: Sue C Bodine, Benjamin F Miller

Funding

  • BLRD VA
  • NIA NIH HHS
  • Veterans Association
  • National Institute on Aging

Cite

APA

O'Reilly, C. L., Bodine, S. C., & Miller, B. F. (2025). Current limitations and future opportunities of tracer studies of muscle ageing. The Journal of Physiology, 603(1), 7-15. https://doi.org/10.1113/jp285616

Vancouver

O'Reilly CL, Bodine SC, Miller BF. Current limitations and future opportunities of tracer studies of muscle ageing. The Journal of Physiology. 2025;603(1):7-15. doi:10.1113/jp285616

BibTeX
@article{OReilly2025,
  author = {O'Reilly, Colleen L and Bodine, Sue C and Miller, Benjamin F},
  title = {Current limitations and future opportunities of tracer studies of muscle ageing},
  journal = {The Journal of Physiology},
  year = {2025},
  volume = {603},
  number = {1},
  pages = {7--15},
  doi = {10.1113/jp285616}
}
Start for free →